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Abstract
Background: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature
given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders.
The emerging field of “immuno-psychiatry” has the potential to widen the exploration of a mechanism-based
nosology, possibly leading to the discovery of more effective personalised treatment strategies.
Discussion: Disturbances in immuno-inflammatory and related systems have been implicated in the aetiology,
pathophysiology, phenomenology and comorbidity of several psychiatric disorders, including major mood disorders
and schizophrenia. A fundamental challenge in their clinical management is to identify bio-signatures that might
indicate risk, state, trait, prognosis or theragnosis. Here, we provide the rationale for a clinical and research agenda to
refine future clinical practice and conceptual views, and to delineate pathways toward innovative treatment discovery.
Conclusion: The development of bio-signatures will allow clinicians to tailor interventions to the abovementioned
biomarker subtypes – a major translational goal for research in this field.
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Background
Despite increasing scientific knowledge and enormous ef-
forts to classify psychiatric disorders, this field is currently
limited by the absence of an articulated neurobiological
substrate to delineate valid diagnostic entities, inhibiting
the development of timely, explanatory, mechanism-based
therapeutic strategies. Further, this constitutes a major
driver for the failure to discover novel therapies for those
with neuropsychiatric disorders [1]. Current diagnostic
schemes for psychiatric disorders are based on descriptive
nomenclature given the absence of clearly defined causal
mechanisms. Such descriptive nomenclature does not eas-
ily include the multiple and successively occurring psychi-
atric and medical comorbidities, nor the considerable
diagnostic instability demonstrated in longitudinal studies.
Disturbances in the immuno-inflammatory system
have been implicated in the aetiology, pathophysiology,
phenomenology and comorbidity of several psychiatric
disorders such as schizophrenia, bipolar disorder, major
mood disorders, suicidal behaviour, post-traumatic dis-
order and autism [2, 3]. Inflammation and activated cell-
mediated immune pathways have consistently been found
in diverse patient cohorts indexed by an up-regulated ex-
pression of pro-inflammatory cytokines [4, 5], triggered and
sustained by environmental risk factors such as very early
infections [6], severe childhood trauma [7] or lifelong psy-
chosocial stressors [8]. It is noteworthy that inflammatory
biomarkers overlap with risk pathways for medical disor-
ders commonly comorbid with psychiatric disorders such
as diabetes, cardiovascular disease and osteoporosis [9]. In
this context, the emerging field of “immuno-psychiatry”
has the potential to widen the exploration of a mechanism-
based nosology, possibly leading to the discovery of more
effective personalised treatment strategies. Herein, we pro-
vide the rationale for a research agenda to refine clinical
practice, including the description of steps to define the
basis of an immuno-psychiatry-based nosology, as well as
pathways toward innovative treatment discovery. We de-
scribe putative research areas and delineate, for each of
them, the current evidence, associated obstacles and re-
search strategies to inform treatment decisions and to build
an agenda for treatment discovery.
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Diagnosis in psychiatry is still restricted to symptoms
and observable signs given the lack of valid biomarkers.
Most biomarker candidates show insufficient sensitivity
and specificity within disorders and overlap greatly be-
tween disorders [10]. Furthermore, diagnostic classifica-
tion does not consider the medical and psychiatric
comorbidities nor the lifetime staging processes [11].
Therefore, efforts to reformulate DSM-5 and ICD-11 nos-
ology should be developed through careful exploration of
possible mechanisms (e.g. dimensions, categories, envir-
onmental risk factors and/or biological markers) and
should lead to, and ultimately be validated by, insightful
and targeted therapeutic strategies. Along the same line,
primary prevention strategies based on the identification
of modifiable environmental risk factors associated with
inflammation need to be conceptualised [2]. It is known
that many of the known risk factors for disorders are
indeed transduced via inflammatory and related path-
ways such as redox biology [2]. Indeed, we would
argue for a common framework of conceptualised
psychiatric disorders among the disproportionally co-
morbid non-communicable medical disorders because
of shared antecedent risks and common biomarkers.
This framework suggests and, as we will later illus-
trate, shows evidence for common treatment and pre-
ventive strategies. Linking cross-clinical dimensional
symptomatology with epidemiological and biological
observations may help refine meaningful new subgroups
using environmental risk factors, such as infections or
stress, to assess medical comorbid disorders and immune
phenotypes to inform treatment.
Auto-immunity, early infection and immune-
genetic background: characterisation for
prevention?
Autoimmune diseases and early infections are well-known
to increase the risk of subsequent psychiatric disorders,
including mood disorders, autism spectrum disorders or
schizophrenia [3, 12, 13]. For instance, a history of hospi-
talisation for infection is known to increase the risk of
later mood disorders by 45 %, while prior history of auto-
immune disorders and infections interact in synergy to
further raise the risk of subsequent mood disorders by
more than 60 % [14]. Maternal history of auto-immune
disorders is also associated with an increased risk of sub-
sequent autism spectrum disorders in offspring of more
than 40 % [15], whereas maternal infections requiring
hospitalisation have been reported in autism spectrum
disorders [16]. Auto-immunity in schizophrenia, affective
psychosis and bipolar disorder has also been reported
[17], thus clearly crossing classical diagnostic boundaries
[6]. Cognitive decline and brain imaging abnormalities
have also been associated with prenatal infections and/or
elevated cytokine levels across disorders [18].
How to translate these findings into an agenda? Not
all subjects that experience early life infection develop
psychiatric disorders. Environmental factors, such as
early infection, could predispose to autoimmune distur-
bances in immunogenetically vulnerable individuals. A
relevant validation strategy would thus be to search for
associations between immunogenetic variants and life
infection history. In animal models, for instance, trans-
genic mice displaying a genetic predisposition to autism
exhibit enhanced responses to environmental challenges
to maternal immune activation [19]. In humans, the
major histocompatibility complex region that includes
the human leukocyte (HLA) genes locus, which has a
crucial role in initiating cellular and humoral immune
responses as well as vulnerability to autoimmune disor-
ders, appears as a major candidate to identify at-risk
subjects. Several HLA genes and haplotypes are linked
to autism [13], while HLA polymorphisms are amongst
the most associated region in schizophrenia [20]. Fur-
thermore, an association between bipolar patients with
autoimmune comorbid disorders and genes encoding
functional Toll Like Receptors (innate immunity) has
been reported [21]. Strengthening the exploration of im-
munogenetic diversity in major psychiatric disorders,
such as innate, adaptive immunity and inflammation
pathways, is urgently needed as has been performed for
cancer [22]. It is necessary to further test gene–gene in-
teractions between risk pathways and the immune and
synaptic pathways as demonstrated in autism [23] and
schizophrenia [24]. This will permit identification of at-
risk individuals and their follow-up along the developmen-
tal exposure to various infections and other environmental
risk factors, additionally suggesting developmental path-
ways for novel therapeutic strategies.
Developmental stress: another factor for
resilience/susceptibility to mental disorders?
Besides the impact of early infections/autoimmune dis-
orders in genetically sensitive subjects, a second “hit”,
such as postnatal stress, also predisposes these individ-
uals to physiological abnormalities mediated by prenatal
immune activation. Indeed, early exposure to trauma in
childhood can increase the subsequent risk of poor func-
tioning of the immune and endocrine systems, which
could constitute risk factors for later depression [7].
Early life stress in humans has been implicated in many
psychiatric disorders in adult life, ranging from depres-
sion to schizophrenia, as well as somatic illnesses ran-
ging from cardiovascular illness and diabetes to
alterations at all levels of the brain–gut axis such as the
altered balance of enteric microflora [25]. Early life stress
is also known to induce long-term alterations in inflam-
matory responses, including elevated C-reactive-protein
and pro-inflammatory cytokines (IL-6, TNF-α, Th1-like)
Leboyer et al. BMC Medicine  (2016) 14:173 Page 2 of 8
[26]. Bipolar patients with a history of childhood trauma
have a more severe form of illness characterised by earlier
age at onset, suicide attempts, rapid cycling, an increased
number of depressive episodes, and higher levels of inflam-
matory markers [27]. Adult vulnerability to neuropsychi-
atric diseases can thus be conceived as being imprinted
during foetal and early postnatal periods through genetic
and/or epigenetic mechanisms [28]. It must be noted at this
juncture that immune regulatory pathways do not operate
singularly, but form part of a complex interacting network
with other pathways, including, but not limited to, redox,
neurogenesis/apoptosis, mitochondrial function and other
stress response pathways [29].
How to translate these findings into an agenda? A sub-
group defined by history of severe and early stress could
be identified by psychological and biological signatures
associating, for instance, elevated levels of cytokines,
cortisol and oxidative stress with specific clinical charac-
teristics. These could be further refined by developmen-
tal animal models in which the phenotypic target of the
pre/postnatal stress model, e.g. specific molecular, be-
havioural or cognitive deficit [30, 31], higher susceptibil-
ity to environmental challenges, or altered impact on
risk and vulnerability pathways [32], will be defined. Life
stressors are likely to occur at different periods, with dif-
ferent origins and intensities, and their impact could also
be tested in these animal models. Furthermore, develop-
mental stress implicates biological mechanisms in which
numerous bodily systems, both peripheral and central,
are engaged. Monitoring these parameters in classical
pre/postnatal stress models and testing the resistance to
stress after manipulations of these parameters will shed
new light on how environmental challenges early in life
may or may not alter resilience and vulnerability path-
ways. Finally, at-risk subjects exposed to early and/or
chronic stressors could also be identified by their immu-
nogenetic markers as known factors for higher risk of
psychiatric disorders (see above). Collectively, we advo-
cate herein that early identification of “high at-risk”
subjects who underwent severe stress events during
childhood will thus open the possibility of prevention
strategies based on changeable environmental risk fac-
tors and restored balance in key biological systems.
Medical comorbidities in major psychiatric
disorders: more than a coincidence?
Comorbidity between psychiatric and medical disorders
is a major issue as it is estimated that approximately 70–
90 % of individuals with bipolar disorder experience a
concomitant psychiatric or somatic disorder [33]. Com-
pared to the general population, metabolic syndrome is
twice more common in patients with bipolar disorder
and schizophrenia [34]. Further, an array of disorders is
more commonly comorbid with depression (e.g. atopy,
cardiovascular disorders, osteoporosis and diabetes). Un-
surprisingly, they all share an inflammatory component
to their aetiology. Although these comorbid patterns
have long been viewed as consequential to an unhealthy
lifestyle or to the side effects of psychotropic drugs, it
has been demonstrated that a pro-inflammatory signa-
ture, with elevated IL-1, IL-6, cortisol and leptin levels
along with obesity, was observed in subjects already at risk
of depressive, bipolar or psychotic disorders [35–37].
Similarly, the large majority of young subjects with autism
spectrum disorders exhibit comorbid patterns, with more
than 90 % suffering of gastrointestinal problems [38]. Ab-
normal metabolic and inflammatory signatures are thus
associated with higher susceptibility for both comorbid
medical and mental disorders [9].
How to translate this observation into an agenda?
Available data strongly suggests that currently defined
psychiatric disorders could be either (or simultaneously)
composed of diverse biological entities fitting under a
same phenomenological spectrum umbrella or different
phenomenological variants of a common underpinning
pathophysiological process. First, we could use advanced
methods, such as systems biology and theoretical “big
data” bioinformatics, to identify new clusters of patients,
integrating the complex phenotypic, anamnestic, psychi-
atric and somatic comorbidities, as well as familial and
environmental risk factors, longitudinal history and bio-
marker profiling to shed light on these heterogeneous
disorders [39]. The oncology field has successfully ap-
plied these techniques to evaluate the relevance of
groups of factors and to identify bio-based clusters
amenable to personalised treatment. Lifespan human
and animal models that take into account the successive
impact of environmental factors are also warranted to
better understand the interactive and/or additive effect
of these factors on the course of psychiatric disorders.
Ideally, biological markers already identified in these dis-
orders or extracted from the above emerging models in
derivation studies could serve to design new “educated
chips” that will contain immune, neurobiological and
genetic markers defining subtypes of patients that could
be further refined in validation studies (Fig. 1).
The use of animal models could facilitate exploration
of in-depth temporal and molecular pathways linking
central and peripheral dysfunctions in psychiatric disor-
ders. For instance, since the discovery that some NMDA
receptor (NMDAR) blockers induce schizophrenia-like
psychosis, reproducing both positive and negative symp-
toms, the NMDA glutamatergic model of psychosis and
schizophrenia has been increasingly accepted as part of
the disease’s etiopathology [40]. The dysfunction of
NMDAR signalling might originate, among other path-
ways, from genetic alteration, autoantibodies directed
against extracellular epitopes [41–46], and/or altered
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levels of endogenous agonists/antagonists (kynurenine
metabolites) [47]. Of note, the recent discovery that auto-
antibodies against extracellular epitopes of the NMDAR
produce major psychosis [41–46] provides a unique op-
portunity to increase our understanding of psychotic
disorders at the molecular, cellular and brain imaging
levels. For instance, autoantibodies from anti-NMDA
encephalitis patients altered NMDAR signalling by pre-
venting molecular interaction and altering membrane traf-
ficking of NMDAR, although without modulating the
function of the NMDAR channel [43]. Thus, NMDAR
dysfunction-induced psychosis could originate from a
blockade of the channel (e.g. phencyclidine) or an altered
trafficking of the receptor (e.g. autoantibodies). Future in-
vestigations in various psychotic disorders will thus shed
new light on the mechanisms underlying these disorders
and pave the way for new, innovative therapeutical strat-
egies to restore proper NMDAR signaling.
Could a common dysfunction be at the origin of per-
ipheral disorders? Theoretically, yes. Indeed, it is often
forgotten that NMDAR is not only expressed in brain
cells but also in many other organs and cell types; for
example, NMDAR is expressed in pancreatic islets and
in insulin-secreting beta cells whose functional impair-
ment contributes to diabetes. A recent study demon-
strated that inhibition of NMDAR in mouse and human
islet cells enhanced their glucose-stimulated insulin se-
cretion and survival [48]. Thus, alterations in NMDAR
signalling might directly confer risk for psychosis and
diabetes. In addition, NMDAR is also expressed at the sur-
face of epithelial barrier cells [49], monocytes [50] and
lymphocytes [51], potentially regulating biological barriers
and immune reactions. Finally, NMDAR is expressed by
cardiac myocytes and cells of the basolateral proximal tu-
bule in the kidney, and its activation in these systems pro-
duces important cellular and organ regulation (see [52] for
a review). Thus, in addition to its well-established role in
the aetiology of major psychiatric disorders, alterations of
NMDAR signalling could also sustain comorbid disorders
in these patients (Fig. 2). Innovative and longitudinal
models urgently need to be implemented in order to in-
vestigate the shared molecular pathways that could link
comorbid somatic and psychiatric disorders as a whole.
Agenda for innovative treatment: new ways to
prescribe existing drugs?
Despite major advances in the understanding of severe
psychiatric disorders, the number of new drugs made
available is steadily declining [53]. Improving our under-
standing of the biological networks and systems associated
with these complex disorders as well as identifying
mechanism-based subgroups among large and complex
psychiatric entities would facilitate a shift towards target-
based high-throughput screening of large compound li-
braries as advocated for drug discovery [1]. If it is
confirmed that subgroups of patients are characterised by
factors such as infections, autoimmunity, inflammation
and immunogenetic-mediated response to environmental
Fig. 1 Schematic illustration of the putative diversity within a psychiatric patient cohort (e.g. schizophrenic ones) diagnosed with a descriptive,
and not mechanistic, nomenclature. The emerging field of immuno-psychiatry has the potential to open up the exploration of mechanism-based
nosology and personalised treatment strategies once multiple variables (e.g. genetic, environmental, biological) are integrated to identify
patient subgroups
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factors, then several existing agents could be prescribed
on the basis of their actions on the immune system [54].
For example, toxoplasmosis is the most common protozoa
parasite infecting people with psychiatric disorders,
with a 2.7-fold increase in overall odds of T. gondii
seropositivity [55], as recently confirmed by a meta-
analysis showing an association with T. gondii antibodies
(immunoglobulin type G) in schizophrenia and obsessive–
compulsive disorder [56]. Remarkably, bipolar disorder
and schizophrenic patients seropositive for T. gondii ap-
pear to have a better outcome when receiving antipsy-
chotics with known in vitro anti-toxoplasmic activity
when compared to patients receiving a treatment without
anti-toxoplasmic activity [57].
One may also repurpose drugs that directly target inflam-
matory pathways to subgroups of patients with immune
phenotypes. For instance, the tetracycline antibiotic mino-
cycline, which exhibits anti-inflammatory, pro-oxidant,
glutamatergic and neurotrophic features, has been
successfully tested in schizophrenia and major depressive
disorders [58, 59]. Both aspirin [60] and non-steroidal
anti-inflammatory drugs (NSAIDs) [59] reduce positive
and negative symptoms of schizophrenia when used as
add-ons to standard antipsychotic therapy, whereas add-
on celecoxib has anti-depressant effects [61]; the efficacy
of NSAID therapy is now supported by meta-analysis [62].
N-acetylcysteine, which has redox, glutamatergic and anti-
inflammatory properties, diminished symptom severity in
add-on studies in schizophrenia and showed antidepres-
sant effects in bipolar disorder and depression [63].
Ketamine and its metabolites worked in depression via
their glutamatergic properties [64] as well as through ro-
bust effects on microglial suppression [65]. It is note-
worthy that high inflammation has been shown to impair,
to a certain extent, the action of antidepressants and anti-
psychotics [66, 67]. Thus, subgroups of psychiatric pa-
tients with infectious and inflammatory conditions should
strongly benefit from adapted therapies, either with direct
anti-inflammatory drugs or with antipsychotics with in-
herent anti-inflammatory properties.
New treatments based on newly-validated targets
The discovery and development of new medications for
clinically and immunologically stratified subgroups of
patients would represent a major breakthrough in the
field of psychiatric disorders. New targets for pathway-
driven nosology will be as important for the future as
the above refined strategies. One may envision that de-
veloping new modulators of specific cytokines (e.g. neu-
tralising interleukins), products of infection-activated
human endogenous retrovirus (e.g. HERV-W), or per-
ipheral and central nervous system receptors (e.g. glu-
tamate NMDAR subunits) would be of great interest for
the subgroup of patients with these immune phenotypes.
Fig. 2 Example of the putative molecular link between medical comorbidities in psychotic disorders. An alteration of the glutamatergic NMDA
receptor signalling, proposed to be central in the aetiology of psychotic disorders, may have varying impact in the various organs of these patients
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For instance, biological immunotherapy that directly tar-
gets cytokines such as IL-6 are worthy of interest since
elevated levels of IL-6 have been reported in and may
serve as markers of both schizophrenia and mood disor-
ders [68]. As antibodies opposing the effects of IL-6 have
been successfully developed for autoimmune diseases,
they are promising candidates for psychiatric disorders,
although probably only in the presence of immune
abnormalities such as elevated levels of IL-6, autoanti-
bodies and infectious stigma. Another targeted immuno-
therapy might be the use of antibodies neutralising the
envelope protein of the human endogenous retrovirus
HERV-W, found elevated in both bipolar disorder and
schizophrenia [69], since the neutralising antibody
GNbAC1 abrogates the HERV-W envelope protein and
has been successfully tested in clinical trials of patients
with multiple sclerosis [70].
Nevertheless, the immense efforts made over the past
decades, in particular by major pharmaceutical compan-
ies, to target the neurotransmitter receptor signalling
pathways extensively correlated to psychiatric disorders
have not paid off. Two new lines of exploration could be
envisioned. First, most efforts have concentrated on the
development of drugs with a direct modulatory effect on
the receptor, whereas an emerging array of evidence
point toward a major defect of neurotransmitter recep-
tor trafficking in brain cells. Focusing on innovative
strategies to restore proper trafficking, and thus signal-
ling, constitutes a promising research area. Second, the
emerging functional interplay between synaptic and
immune receptors, supposedly involved in brain connec-
tion maturation during development [71] and psychiatric
disorders [72], should prompt us to build mechanistic
and integrated models to leverage the immense potential
of the genome-wide association studies highlighting the
interconnection between neurotransmission and im-
munity in psychiatric disorders.
Conclusion
Beyond the enormous economic burden that psychiatric
disorders represent, the discovery of alterations in the
intimate molecular networks that sustain the diseases
and their application to develop novel therapeutic strat-
egies is one of the most exciting and key scientific chal-
lenges for the 21st century. Here, we advocate that the
path to discovery would first require a “deconstruction”
of current practices to segment psychiatric disorders and
we suggest elements of a research agenda to adapt clin-
ical practice and foster research paradigms. The grounds
for reconstruction should be based on the integration of
a reconciled body–brain interface leading to a new
“immuno-psychiatry-based nosology”. Indeed, the accu-
mulating evidence that immune and environmental al-
terations play a key role in the aetiology of seemingly
diverse disorders provides a promising opportunity to
define latent subgroups that share immune, genetic and
brain alterations. Innovative animal models are within
our grasp to fully identify and properly address emerging
obstacles. The opportunities for therapeutic strategies,
both by re-purposing existing drugs and by identifying
targets with new angles, may be immense and could pro-
vide the necessary hope that clinicians, pharmaceutical
companies and, most importantly, patients may have
gradually lost over the past decades.
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